ESSA Pharma Inc.
Develops drugs targeting the androgen receptor's N-terminal domain for prostate cancer.
EPIX | US
Overview
Corporate Details
- ISIN(s):
- CA29668H7085
- LEI:
- Country:
- United States of America
- Address:
- SUITE 720, 0 VANCOUVER
- Website:
- https://www.essapharma.com/
- Sector:
- Manufacturing
Description
ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on the development of small molecule drugs for the treatment of prostate cancer. The company's core strategy is to develop novel therapies that target the N-terminal domain (NTD) of the androgen receptor (AR). This approach represents a distinct mechanism of action compared to existing treatments that target the ligand-binding domain of the AR. Its lead clinical candidate, EPI-7386, is an investigational oral drug designed to inhibit AR activity and is being developed for patients with castration-resistant prostate cancer (CRPC), including those whose disease has become resistant to current standard-of-care therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ESSA Pharma Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ESSA Pharma Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ESSA Pharma Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
